Main menu

Oxford Nanopore Technologies and BugSeq announce collaboration to provide fully automated analysis solutions for rapid pathogen identification and antimicrobial resistance


Combination of leading nanopore sequencing technology with cloud-based SAAS analysis platform will help microbiologists gain critical infectious disease insights from genomic data

Oxford Nanopore Technologies (Oxford Nanopore) the company behind a new generation of molecular sensing technology based on nanopores, and BugSeq, a leading provider of fully automated infectious disease bioinformatics services, today announced a collaboration aimed at delivering rapid and accurate analysis solutions for microbiology labs. This collaboration seeks to enable labs to gain critical insights from their genomic data, including pathogen identification, outbreak investigation, and antimicrobial resistance profiling.

Under the terms of the agreement, the two companies will provide a seamless end-to-end solution for pathogen analysis combining nanopore sequencing with BugSeq’s cloud accelerated “software-as-a-service” analysis platform. By leveraging the unique capabilities of both platforms, microbiology labs will be able to accelerate sample-to-answer workflows, enabling prompt and effective responses to pathogens and emerging threats.

"We are excited to partner with BugSeq to bring forth innovative, user-friendly solutions that address the evolving needs of microbiology labs,” said Gordon Sanghera, CEO, Oxford Nanopore Technologies. “Together, we aim to empower labs with the tools and capabilities needed to accelerate the identification of pathogens and antimicrobial resistance, ultimately enhancing public health outcomes."

Oxford Nanopore's platform, which is capable of rapidly sequencing long DNA fragments, will be complemented by BugSeq's suite of user-friendly solutions, leading accuracy analysis and curated databases. Integrating these technologies enables recovery of complete microbial genomes and plasmids, antimicrobial resistance prediction, and metagenomic analyses capable of detecting any pathogens within a sample.

​​​"This collaboration builds off BugSeq's industry-leading bioinformatic platform and expertise to enable advanced detection and characterisation of infectious diseases,” said Sam Chorlton, CEO of BugSeq. "By combining our strengths with Oxford Nanopore's cutting-edge sequencing technology, we are poised to redefine the standards of microbiology sequencing analysis."

For more information, please watch the on-demand webinar: Real-time infectious disease outbreak investigations with nanopore sequencing and BugSeq analysis

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag